Trophos completes patient enrolment in pivotal efficacy study of olesoxime in Spinal Muscular Atrophy

September 8, 2011

Trophos completes patient enrolment in pivotal efficacy study of olesoxime in Spinal Muscular Atrophy

Press Release | September 8, 2011

Marseille France, September 8, 2011 – Trophos SA, a clinical stage pharmaceutical company developing innovative therapeutics from discovery to clinical validation for indications with under-served needs in neurology and cardiology, announced today the completion of patient enrolment in the pivotal efficacy study of olesoxime in the rare neurodegenerative condition Spinal Muscular Atrophy (SMA). Over 160 patients have been recruited into the trial since its initiation in October 2010. The study is substantially funded by Trophos’ partnership with the Association Française contre les Myopathies (AFM) (see release of 19 March 2009). The trial protocol has benefited from the EMA protocol advice procedure. Efficacy results are expected in the second half of 2013.

“The completion of recruitment in this pivotal clinical study in only ten months given the rarity of SMA is a great achievement and a major step in the development of olesoxime as a potential treatment for SMA,” said Jean-Louis Abitbol, chief medical officer at Trophos. “SMA is a debilitating and disabling neuromuscular disease and there is a critical need for a treatment that can slow down or prevent the loss of muscle function in SMA patients, for whom no specific treatment exists today. Over 160 patients have been included in the study in only ten months, which reflects both the great commitment of patients and clinicians to find a treatment for SMA and the motivation and hard work of all involved. We anticipate the results of the trial in the second half of 2013 and hope this will be a historic moment for the medical community as well as those affected now and in the future.”

“Thanks to the donations to the French telethon, we have been supporting the development of olesoxime since the first screening up to and including the ongoing clinical phases. The recruitment in this important clinical study has just been completed with great efficiency and brings hope for a first potential treatment to SMA patients,” said Christian Cottet, CEO, AFM.

“Trophos and the AFM been working together for over a decade and this crucial clinical study with Trophos’ olesoxime in SMA is the fruit of our long standing partnership,” said Damian Marron, CEO, Trophos. ”Olesoxime has a promising profile as a potential treatment for SMA and we are hopeful the results of this study will demonstrate that promise, bringing a much needed treatment option and new hope to SMA patients and their families. This study as well as our soon to be completed pivotal study of olesoxime in amyotrophic lateral sclerosis (ALS) underlines Trophos’ commitment to developing breakthrough therapies for rare and serious neurodegenerative diseases.”

Click HERE or on the image below to read more…


Trophos Presents Data At The American Academy Of Neurology On SMA And MS

April 15, 2011

Trophos Presents Data At The American Academy Of Neurology On SMA And MS

Medical News Today | April 14, 2011

Trophos SA, a clinical stage pharmaceutical company developing innovative therapeutics from discovery to clinical validation for indications with under-served needs in neurology and cardiology, announces today that Trophos has described the design of its pivotal clinical study of olesoxime in spinal muscular atrophy (SMA) via a poster presentation at this week’s 6th Annual American Academy of Neurology (AAN) meeting held in Honolulu, Hawaii, US, April 9 to 16, 2011. In addition at the conference, Trophos also delivered an oral presentation detailing Trophos’ novel approach in multiple sclerosis (MS). Both the paper and oral presentation were delivered at the conference on April 14.

The poster, on the pivotal efficacy study of olesoxime in the rare, neurodegenerative condition, SMA, demonstrates how the challenges of designing a robust study in an indication where there is no precedent were met by bringing together and working with key opinion leaders, patient and physician networks and regulators. The study commenced in October 2010 (see release of October 15 2010) and is currently recruiting patients. Efficacy results are expected in the second half of 2013. The study is substantially funded by Trophos’ partnership with the Association Française contre les Myopathies (AFM) (see release of 19 March 2009) and the trial protocol has benefited from the EMA Protocol Advice procedure.

Click HERE or on the image below to read more…